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Abstract
Background: Various pathways involved in the pathogenesis of sJIA have been identified through gene expression
profiling in peripheral blood mononuclear cells (PBMC), but not in neutrophils. Since neutrophils are important in
tissue damage during inflammation, and are elevated as part of the acute phase response, we hypothesised that
neutrophil pathways could also be important in the pathogenesis of sJIA. We therefore studied the gene profile in
both PBMC and neutrophils of sJIA patients treated with tocilizumab.
Methods: We studied the transcriptomes of peripheral blood mononuclear cells (PBMC) and neutrophils from eight
paired samples obtained from 4 sJIA patients taken before and after treatment, selected on the basis that they achieved
ACR90 responses within 12 weeks of therapy initiation with tocilizumab. RNA was extracted and gene expression
profiling was performed using Affymetrix GeneChip Human Genome U133 Plus 2.0 microarray platform. A longitudinal
analysis using paired t-test (p < 0.05 and FC ≥ 1.5) was applied to identify differentially expressed genes (DEGs)
between the two time points followed by ingenuity pathway analysis. Gene Set Enrichment Analysis (GSEA)
and quantitative real-time PCR were then performed to verify the microarray results.
Results: Gene ontology analysis in neutrophils revealed that response to tocilizumab significantly altered genes
regulating mitochondrial dysfunction and oxidative stress (p = 4.6E-05). This was independently verified with
GSEA, by identifying a set of oxidative genes whose expression correlated with response to tocilizumab. In
PBMC, treatment of sJIA with tocilizumab appeared to affect genes in Oncostatin M signalling and B cell
pathways.
Conclusions: For the first time we demonstrate that neutrophils from sJIA patients responding to tocilizumab
showed significantly different changes in gene expression. These data could highlight the importance of
mitochondrial genes that modulate oxidative stress in the pathogenesis of sJIA.
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Background
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group
of arthritides classified into 7 subtypes by the International
League of Associations for Rheumatology (ILAR) [1]. We
have previously examined the transcriptome of patients
with systemic JIA (sJIA), a distinct clinical subgroup with
characteristic systemic inflammation as well as arthritis [2].
Systemic inflammatory features of this group of patients
include quotidian fever, evanescent skin rash, lymphaden-
opathy, serositis and hepatosplenomegaly. These clinical
features are reminiscent of the heritable autoinflammatory
diseases; consequently, sJIA is frequently referred to as an
autoinflammatory disease because of these clinical
manifestations, lack of autoantibodies, and association
with variants in inflammatory and anti-inflammatory
cytokine genes, including IL-1, IL-6, and IL-10 [3–8].
High or abnormal production of inflammatory cyto-
kines in the plasma, and impressive results from clinical
trials to modify IL-1 and IL-6 cell signalling have pro-
vided further evidence for the important roles of these
cytokines in the pathogenesis of sJIA [9–17].
The molecular pathways leading to the symptoms of
sJIA are not yet fully understood, but have been clarified
to some extent during recent years by the use of micro-
array technology. So far, gene expression studies have been
performed mostly on peripheral blood mononuclear cells
(PBMC) from sJIA patients, with the exception of one
study which examined whole blood [18]. Studies of this
nature have led to the identification of gene clusters asso-
ciated with disease activity [2] and severity [19], and re-
vealed dysregulation of cytokine pathways [9, 12, 18]. A
study applied DNA microarray methods across different
subtypes of JIA, and identified patterns of gene expression
that correlated with clinical characteristics of the different
subtypes. In particular, it was shown that sJIA is distinct
from Oligoarticular and Polyarticular JIA [20]. Further-
more, gene expression profiles in neutrophils from chil-
dren with polyarticular JIA demonstrate defects in genes
modulated by IFN-gamma and IL-8 [21–23].
Since many autoinflammatory diseases involve the
genes and pathways of the innate immune system, we
proposed that neutrophils were worthy of further
study in sJIA. Neutrophils are highly specialised leuco-
cytes that mediate inflammatory changes in tissues,
and are important effectors of innate/early immune
responses [24]. Once activated, neutrophils can pro-
duce reactive oxygen species that neutralise the effects
of bacteria and fungi, and together with chemokines
and other inflammatory mediators, orchestrate inflam-
mation in tissues [24]. In autoinflammatory diseases,
abundant neutrophils are usually seen in sites of inflam-
mation, often in the relative absence of lymphocytes
[25, 26]. Consequently, we hypothesised that neutro-
phils are important in the pathogenesis of sJIA, and
that there would be important differences in the dif-
ferentially expressed genes in response to tocilizumab.
Methods
Patients and treatment
This pilot study included symptomatic sJIA patients
with disease duration ranging from 9 months to 7
years (Table 1), who were selected for analysis on the
basis that they achieved an adapted American College
of Rheumatology response of 90 (ACR90) to tocilizumab.
The clinical features of the patients in this study are
shown in Table 1. All patients provided written informed
consent to enter this observational study, with ethical ap-
proval by Great Ormond Street Hospital for Children
NHS Trust (GOSH)/Institute of Child Health Research
Ethics committee (registration number 02RU06). We ex-
amined gene expression profiles before, and 3 months
after treatment with tocilizumab (a humanised monoclo-
nal antibody targeting the interleukin 6 receptor, received
as routine clinical care) at GOSH. The patients received
tocilizumab using a standard recommended dosing regi-
men [14, 16]; samples from responders were collected
from November 2008 to July 2009. All patients fulfilled
sJIA ILAR classification criteria [27]. Patients were consid-
ered for this study group if they had persistent signs of
inflammation refractory to therapy with methotrexate
(MTX), with or without corticosteroid or anti-TNF-α
therapy. Blood samples referred to as “Before” were ob-
tained from all patients at routine baseline screening prior
to the initiation of treatment when the disease status was
active. Twelve weeks from enrolment into the study, an
“After” sample was collected. Clinical assessment of
disease activity was determined using the JIA core set cri-
teria and definition of improvement [28]. The American
College of Rheumatology (ACR) paediatric adapted im-
provement score was then calculated at the time of sample
collection (28). Response was defined as: paediatric-
adapted American College of Rheumatology (ACR) 90
response, plus normalisation of the C reactive protein
(CRP) and erythrocyte sedimentation rate (ESR).
Leucocyte separation
PBMC were obtained from Ficoll separation of whole
blood using Lymphoprep reagent (Stemcell Technologies).
Neutrophils were subsequently isolated from the granulo-
cyte and red cell pellet formed at the bottom of the Ficoll
tube by hypotonic cell lysis in ammonium chloride buffer.
Cell viability was assessed by trypan blue dye exclusion.
Purified cells were visualised and counted using a haemo-
cytometer before re-suspension in TRIzol reagent (Invi-
trogen, Paisley, UK). Care was taken to minimize the time
between blood-drawing and placing cells in TRIzol
reagent to within 3 h.
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Assessment of purity and the effect of isolation process
on neutrophil activation status
We used two-colour flow cytometric analysis to moni-
tor ex vivo activation of neutrophils as a result of
sample manipulation. Antibody staining for surface
markers was performed as previously described [29],
using PE conjugated mouse Anti-Human CD11b/Mac-1
(a marker to monitor ex vivo activation of neutrophils),
and APC-Cy7 mouse Anti-Human CD16, expressed
on the surface of neutrophils. A FACScan flow cyt-
ometer and CellQuest analysis software were used for
the acquisition and analysis of the data. The purity
and activation status of isolated neutrophils were
evaluated by gating on the CD11b/Mac-1 and CD16
double-positive cells.
Lipopolysaccharide-induced activation of isolated
neutrophils
Isolated neutrophils at a density of 2 × 106 cells/ml
in RPMI were cultured at 37°C for 1 h in the pres-
ence or absence of 1μg/ml lipopolysaccharide (LPS).
The level of neutrophil activation was again evaluated
by flow cytometry analysis of CD11b/Mac-1 on CD16
positive cells.
Microarray procedures
The protocols for RNA extraction and microarray
hybridization to Affymetrix U133 plus 2.0 arrays
(Affymetrix, Santa Clara, CA), which includes approxi-
mately 54,000 probe sets representing 47,400 human tran-
scripts were as previously described [2]. Processing of
Affymetrix data was performed in GeneSpring GX11.0
(Agilent) using GCRMA (RMA; Robust Multi-array Ana-
lysis that accounts for the probes GC content) method for
normalizing and summarizing probe-level intensity mea-
surements [30]. Probe sets with very low absolute expres-
sion intensity values (<10) in all patients in either the
“before” or “after” samples were filtered out since at this
level it would be difficult to distinguish a true effect from
background noise [31]. Multiple probe sets mapping to the
same gene that passed this filter were retained and the dif-
ferential expression of any probe set for a given gene was
used as a surrogate for differential gene expression. The
affymetrix data files have been submitted to NCBI Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/) under accession number GSE76492.
Statistical analysis of microarray data
Paired t-test of the "before" and "after" treatment samples
at statistical threshold of p < 0.05 with fold-change (FC)
Table 1 Clinical features of patients and response to tocilizumab
Sample code 37-5 37-7 50-2 50-4 51-1 51-3 53-2 53-4
Sample type N N P, N P, N P, N P, N P, N P, N
Conditions Pre-TOC 12 weeks TOC Pre-TOC 12 weeks TOC Pre-TOC 12 weeks TOC Pre-TOC 12 weeks TOC
Ethnicity Caucasian Caucasian Asian Caucasian
Gender Male Female Male Female
Age at onset (AAO) 7 years 9 years 14 years 4 years
Disease duration 3.4 years 7 years 10 months 9 months
Fever Yes No No No No No Yes No
Rash Yes No No No No No No No
Total WCC (lymphocytes) x 109/L 22.22 (1.36) 10.76 (4.99) 10.51 (1.28) 5.58 (2.67) N/D 5.84 (2.52) 13.98 (4.80) 8.09 (4.03)
CRP (mg/l), 0-20 normal range 84 <5 24 <5 13.6 <3 56 <5
ESR (mm/h), 0–10 normal range 65 <1 29 3 N/D 1 35 <1
Joint active 6 0 22 10 6 0 51 0
Joint limited motion 6 0 30 12 7 0 49 3
Parental VAS N/D 0 6.8 1 2.8 0.4 5 2.2
Physician VAS 5 0 8 4 3 1 8 0.4
CHAQ 1.75 0 1.5 0.38 0 0 1.13 0.5
ACR - 90 - 90 - 90 - 90
The demographics, clinical and laboratory parameters of the patients whose peripheral blood was used in this study are shown. For each patient, baseline
measurements were taken before starting tocilizumab (TOC) treatment, and 12 weeks later. Normal range for total white cell count (WCC) is 4.5–13.5 × 109/L and
for lymphocytes 1.5–7 × 109/L. The different types of samples taken/analysed were: PBMC = P; and Neutrophils = N. There are 3 paired samples for PBMC (P) and 4
for neutrophils (N). Response to treatment was determined by ACR90 response definition of improvement in juvenile arthritis [47], plus normalisation of the
erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). N/D not determined, VAS visual analogue score, CHAQ child health assessment questionnaire,
ACR American College of Rheumatology
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≥1.5 was considered as significant for identification of
differentially expressed genes. Both unsupervised and
supervised hierarchical clustering was performed using
Pearson’s centered correlation and Ward’s linkage rule
within GeneSpring software to generate heatmaps of gene
expression profiles.
Ingenuity Pathway Analysis (IPA)
The differentially expressed probe sets identified with statis-
tical testing were uploaded into the IPA knowledge data-
base (version 7.2, Ingenuity® Systems, www.ingenuity.com)
to explore the pathways that were significantly associated
with each dataset. In the case of multiple probe sets
mapping to the same transcript, IPA considered the probe
set with the highest fold change for the pathway analysis.
Each annotated gene was mapped to its corresponding
gene object in the IPA Knowledge Base. The Affymetrix
U133 plus 2.0 array was selected as background or refer-
ence dataset for calculation of significant functions/path-
ways. The core analysis was run using the following setting
in IPA: data source included all species, tissues and cell
lines; interactions were queried on all genes stored within
IPA; and no fold-change cut-off was specified. The signifi-
cance of the association between the data set and the
canonical pathways was calculated in 2 ways according to
IPA user’s manual: 1) a ratio of the number of genes from
our dataset that map to the pathway, divided by the total
number of genes that make up the pathway; 2) Fisher’s
exact test was used to calculate a p-value determining the
probability that the association between the genes in the
data set and the canonical pathway was explained by
chance alone. A pathway was considered significant with a
p-value that was less than 0.05. All pathways were named
according to the terminology used in IPA.
Gene Set enrichment analysis of microarray data
GSEA was performed using gene sets from MSigDB v2.5
gene set database (http://www.broadinstitute.org/gsea/
msigdb/). This analytical technique is designed to test a
priori defined gene sets (for example, pathways) for asso-
ciation with phenotypes [32]. In brief, the method
consists of the following steps: list of genes are first
ranked by Signal2Noise metric using the correlation
between their expression and the class distinction (for
example, “before” versus “after” treatment samples).
Given a defined set of genes (for example, genes mem-
bers of a signalling pathway), the goal of GSEA is to
determine whether the members of the gene set are
found at the top or bottom of the list, indicating that
they are associate with the phenotypic distinction, rather
than being distributed uniformly or randomly across the
list. An enrichment score is then calculated to quantify
the degree to which a gene set is over-represented at the
top or bottom of the entire ranked list. After calculation
of the enrichment scores, statistical significance test was
done with 1, 000 permutation of genes using the weighted
to enrichment statistic.
Quantitative real-time (qRT-PCR)
cDNA was generated from 500ng of total RNA using High
Capacity RNA-to-cDNA kit (Life Technologies) according
to the manufacturer’s instruction. qRT-PCR assays were
performed using QuantiTect SYBR Green PCR kit and the
following commercially available QuantiTect primers: (Qia-
gen, Crawley, UK) for COX6C (Assay ID QT00221137),
NDUFB2 (Assay ID QT00050904), and LAT (Assay ID
QT00232127). Differences in expression were determined
by the relative quantification method; the cycle threshold
(CT) values of the target genes were first normalised to the
CT values of endogenous control large ribosomal protein
P0 (RPLPO, Assay ID QT00075012).
Results
Patients
This exploratory analysis included only sJIA patients
with active symptomatic disease who were selected on
the basis that they responded (by attaining ACR90) to
tocilizumab (Table 1). All the patients described herein
additionally had normal CRP/ESR at second sample col-
lection with an ACR90 response, and therefore all were
considered as responders for the purposes of this study.
Identification of genes/pathways associated with good
response to tocilizumab
After filtering out unreliable probe sets with expression
at background level, 23,895 and 20,408 out of 54,459
probe sets were considered as expressed in PBMC and
neutrophils respectively. Unsupervised hierarchical cluster-
ing (HC) of all expressed genes showed that the pre- and
post-treatment samples from the patients (3 sJIA patients
for PBMC samples and 4 sJIA patients for neutrophils)
clustered together for each cell type (data not shown).
Therefore, paired t-test of gene expression in each in-
dividual before and after treatment is preferred for
the analysis of change over time (with statistical cut-
off level of p < 0.05 with ≥ FC 1.5) to cross sectional
analysis of the time points. The full lists of the genes
are given in Additional files 1 (for PBMC) and 2 (for
neutrophils). We performed supervised HC of the
differentially expressed probe sets in PBMC and neu-
trophils separately, and generated heatmaps to illus-
trate the expression pattern between the two time
points (Fig. 1a-b). This analysis yielded two main
clusters of probe sets for each of the 2 cell types;
cluster 1 for probe sets with decreased expression at
12 weeks, and cluster 2 corresponding to probe sets
with increased expression at 12 weeks.
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We used Ingenuity Pathway Analysis (IPA) tools to
identify the significant pathways (p < 0.05) associated
with the 2 lists of differentially expressed probe sets in
PBMC and neutrophils. A summary of the results are
presented in Table 2 for the top 10 IPA canonical path-
ways presented in order of significance.
PBMC gene expression profiling in tocilizumab treated
patients showed changes in pathways associated with IL-6
signalling
Only 18 genes out of 385 differentially expressed unique
genes in PBMC of sJIA patients were significantly mapped
to 6 IPA canonical pathways (Table 2, Additional file 3).
The most significant pathway was the Oncostatin M sig-
nalling pathway from this analysis; p = 0.015, with 3
mapped genes (IL6ST, KRAS, CHI3L1).
Neutrophil gene expression profiling demonstrated changes
in mitochondrial and T cell pathways
The most significant change in IPA pathway for neu-
trophils was the “mitochondrial dysfunction pathway”
(p = 0.000046) with increased expression of 20 genes in re-
sponse to tocilizumab treatment (Table 2, Additional file 4).
Fig. 1 Heatmaps illustrating supervised hierarchical clustering analysis of the probe sets differentially expressed in PBMC (a) and Neutrophils (b) from
sJIA patients before and after tocilizumab treatment (3 sJIA patients for PBMC samples and 4 sJIA patients for neutrophils). The differential expression
of any probe set for a given gene was used as a surrogate for differential gene expression. Samples were collected at time points zero, and 3 months
post treatment. All were responders with ACR90 (Table 1). Clustering analysis was performed in GeneSpring (GX11) as described in Methods.
Normalized expression is colour coded in which red is high and blue is low relative to the median of the ‘before’ treatment samples. In the
heatmaps, each column represents a sample and each row represents a gene. Full list of all genes in clusters are available in Additional files 1
and 2. However, listed below are genes with fold change (FC) ≥3 found within the clusters in the order of decreasing FC values. A cluster 1:
Genes with significant decrease (FC ≥ 3 fold) after treatment with tocilizumab in PBMC: FCGR3B, KCNJ15, CHI3L1, ADM, PROS1, SOCS3, CHI3L1,
and NRG1. A cluster 2: there were genes with increased expression on the heatmap but these were all less than 3 fold change. B cluster 1:
Genes with significant decrease (FC ≥ 3 fold) after treatment with tocilizumab in neutrophils: ARHGAP24, CLEC5A, TAF8. B cluster 2: Genes with
significant increase (FC ≥ 3 fold) after treatment with tocilizumab in neutrophils: CD3D, LOC129293, AQP3, LAT, LY9, HLA-DPB1, TRA@, GFI1B,
BCL11B, PASK, POLR3E, DOK2, AFG3L2, MEX3C, PASK, ENTPD6, KIAA0114, FAM102A, RCAN3, ATXN10, TNFAIP8L1, ABHD14B, RPL10A, GPR44, ATP6V0E2,
ADARB1, APEX1, C17orf61, KLHL3, MRPS24, POU6F1, LDLRAP1, NDUFB2, SLC25A38, UBQLN4, KLF10, C22orf32, AKR1B1, PPP3CC, GSS, CAMK1, EIF3C,
EEF2K, ILF3, RPL13, SLC25A6, THEM4, RPL13A, RDH14, KCTD15, DNMT1, TTC4, KIAA0748, AKR7A2, PLSCR3, ZNF639, KIAA1024, UNC84A, IARS, C11orf31,
PVT1, DNPEP, LOC202781, LAGE3, NHP2, LSG1, SIRPG, SLC35B2, EEF2K, AES, TMEM14A, PAN2, DDX39, NOC4L, CAMSAP1, LOC100131731, BHLHE40,
ECHS1, CLNS1A, CPSF1, LOC93622, TOMM5, COX6C, NLRC3, EIF3B, CIRH1A, OLIG1, ZBTB40
Table 2 Top ten IPA pathways that were found to be significantly
altered in PBMC and neutrophil samples from sJIA patients
responding to tocilizumab
PBMCa Neutrophils
Oncostatin M signalling (3) Mitochondrial dysfunction (20)
Natural killer cell signalling (5) EIF2 signalling (23)
Glutamine biosynthesis I (1) NRF2-mediated oxidative stress
response (20)
B Cell receptor signalling (6) Calcium-induced T lymphocyte
apoptosis (9)
PPARα/RXRα activation (6) mTOR signalling (20)
Thyroid hormone biosynthesis (1) Sucrose degradation V (Mammalian) (3)
Regulation of eIF4 and p70S6K
signalling (16)
TCA cycle II (Eukaryotic) (5)
CTLA4 signalling in cytotoxic T
lymphocytes (11)
Protein ubiquitination pathway (24)
aThere were only 6 significant canonical pathways for this condition. In
brackets are the numbers of genes from the input file in each pathway
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These genes included ATP5A1, an ATP synthase of com-
plex V, and 13 other genes that code for subunits of other
mitochondria respiratory chain complexes. In complex I
there was increased expression of 8 nuclear encoded
NADH dehydrogenase genes of which NDUFB2 had the
highest FC value of 3. Ubiquinol-cytochrome c reductase
(UQCRH) coding for a hinge protein was the only gene reg-
ulated in complex III; in complex IV there was increased
expression of nuclear encoded cytochrome c oxidase;
Cox5A, Cox6C and Cox7C. The expression of linker for
activated cells (LAT) was significantly increased 6-fold in
response to tocilizumab treatment, and this gene was also
mapped to two significant T cell pathways; CD28 Signalling
in T Helper Cells and Regulation of IL-2 Expression in
Activated and Anergic T Lymphocytes.
GSEA shows enrichment of mitochondrial/oxidative
phosphorylation genes in sJIA patients treated with
tocilizumab
We analysed the microarray data by GSEA [32] to deter-
mine whether the differential expression of mitochondrial
genes observed in neutrophils of sJIA patients treated with
tocilizumab were truly representative of the global gene
expression data without regard to the accuracy of
statistical threshold applied in the initial analysis. For
GSEA, we extracted from MSigDB v2.5 gene set data-
base (http://www.broadinstitute.org/gsea/msigdb/) the
KEGGS_oxidative phosphorylation gene set which origin-
ally contained 135 genes, but the analysis was restricted to
110 genes present on the Affymetrix U133 plus 2.0 chip.
This gene set was chosen because it is the best representa-
tive of the IPA mitochondrial dysfunction pathway as it
contains 12 of the 20 genes mapped to this pathway
(indicated with an asterisk in the Additional file 4).
The result of GSEA showed significant enrichment of
the oxidative phosphorylation gene set (Additional file 5
for the gene list) with increased expression of the leading
edge gene subset in sJIA patients post tocilizumab treat-
ment (Fig. 2a, b).
Verification of Microarray analysis by qRT-PCR
Given the limitation in the blood sample volume, it was
only possible to verify the accuracy of our microarray
analysis by real-time quantitative PCR on just the neu-
trophil samples used in the array experiment. The qRT-
PCR results confirmed the microarray data for COX6C,
LAT and NDUFB2 (Fig. 2c).
Minor change in neutrophil activation following sample
manipulation
Before the microarray analysis of gene expression in neu-
trophils, we carried out a series of control experiments
where we compared expression level of the neutrophil
activation marker CD11b/Mac-1 measured in geometric
mean fluorescence intensity (GMFI) on CD16+ cells gated
on granulocytes population within whole blood to that of
isolated neutrophils ±1μg/ml LPS by flow cytometry.
These experiments were performed in healthy controls as
well as sJIA patients with active and inactive disease.
There was a small increase in CD11b expression due to
Fig. 2 Genes associated with oxidative phosphorylation (mitochondria function). a Enrichment plot of KEGG_Oxidative phosphorylation gene set
identified by GSEA. Middle section (black bars) illustrate the position of the genes belonging to the gene set in the context of all the genes on the
Affymetrix U133 plus 2.0 array. The enrichment score (ES) plotted as a function of the position within the ranked list of array genes is shown as
a green line. The ranked list metric shown in gray illustrates the correlation between the signal to noise values of all individually ranked genes
according to the neutrophil samples of the ‘before’ and ‘after’ tocilizumab treatment (experimental conditions). b on the left is GSEA-
derived heat map of the 110 leading edge genes that correlates with response to tocilizumab and contributing to the enrichment score; on the
right is the top 20 genes that includes some of the genes mapped by IPA to mitochondria dysfunction pathway (in red asterisks). Signal intensities are
illustrated by varying shades of red (increased) and blue (decreased). c Quantitative real-time polymerase chain reaction (qRT-PCR) validation of differ-
entially expressed genes (NDUFB2, COX6C, LAT) observed in this microarray experiment. The relative fold change of both microarray (solid bar) and qRT-
PCR (open bars) are shown. The data for qRT-PCR are the average of 3 independent experiments done on the same sample
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the separation process. However, neutrophils were still
relatively inactive since they were highly sensitive (>10
fold increase) to further activation when stimulated
with LPS in both healthy controls and sJIA patients
(Additional file 6). The purity of isolated neutrophils
as defined from the double positive cells was >96 %
(Additional file 7). The median ± standard deviation
(SD) of double positive isolated neutrophils for all the
sJIA samples was 96.55 % ± 0.63 compared to 60 % ±
6.89 in whole blood (Additional file 7).
Discussion
A novel and important aspect of this study is that we ex-
amined neutrophils in addition to PBMC since these cells
are known to play important roles in innate immune
responses and the pathogenesis of sJIA [33–35], but previ-
ously have not been studied by transcriptome analyses in
this context. Both IPA and GSEA showed significant cor-
relation between mitochondrial/oxidative stress genes and
response to tocilizumab in neutrophils of sJIA patients.
Our microarray data indicated a significant increase in the
expression levels of nuclear encoded mitochondrial genes
that are involved in electron transport (e.g. NDUFB2,
COX6C, both confirmed by q RT-PCR) after a good clin-
ical response to tocilizumab; or conversely, that decreased
gene expression was present in those with active disease.
This observation is consistent with the study by Ishikawa
et al. using whole blood for gene profiling, showing re-
duced expression of mitochondrial DNA-encoded genes
in sJIA patients with active disease compared to healthy
controls [18]. They did not detect differences in any of the
nuclear encoded genes including those found in this study,
which might be due to differences in study design, analysis
of a mixed cell population of whole blood (PAXgene) sam-
ples, microarray platforms and/or analytical methods
used. Our data are further supported by the fact that IL-6
has been shown to have a direct effect on mitochondrial
function by decreasing both the membrane potential and
ATP production with subsequent increase in intracellular
reactive oxygen species (ROS) level in an in vitro study
[36]. Currently, there is growing evidence that mitochon-
drial ROS and defective antioxidant responses play an
important role in the pathogenesis of a number of autoin-
flammatory and autoimmune diseases [37–42]. Given that
IL-6 is one of the most important mediators of fever and
the acute phase response (including neutrophilia), and
that neutrophil mitochondrial ROS are increasingly
understood to be important in autoinflammation, it is
perhaps unsurprising that we have detected perturbation
of mitochondrial genes in neutrophils in active sJIA,
which change in response to successful therapy with IL-6
blockade. This further emphasises the potential import-
ance of studying neutrophils in sJIA and its response to
treatment in the future.
It was striking and unexpected to observe the differen-
tial expression of T-cell receptor associated genes such
as delta 3 molecule (CD3D), zeta-chain tyrosine kinase
(Zap70) and linker for activation of T cell (LAT, con-
firmed by q RT-PCR) in the neutrophil cell population
from patients treated with tocilizumab. Although we
cannot rule out minor and uneven contamination of the
separated cell populations by T cells, previous studies
have revealed that human neutrophils do express TCR
including components of the signalling complex [43, 44],
but their exact role in neutrophils is not yet known. Our
microarray data showed that LAT is expressed in neutro-
phils of all the 4 patients studied. Furthermore Puellmann
et al. addressed the issue of contamination by clearly
demonstrating that the neutrophil cell populations were
negative for T cell markers (CD3, CD4, and CD8) [44].
These findings suggest that neutrophils may have the
potential to mediate both innate and adaptive immune
responses in sJIA patients.
It was reassuring to note that in the DEGs from the
PBMC of tocilizumab-treated sJIA patients, there was
decreased expression of SOCS3, a suppressor of cytokine
signalling, consistent with the fact that tocilizumab
decreases intracellular IL-6 signalling and therefore
reduction in the expression of SOCS3. We have previ-
ously reported that specific innate immune genes are
upregulated in PBMC of sJIA patients during active dis-
ease [2]. In the same study we also demonstrated that B
cells express higher levels of IL-6 than monocytes. Given
the heterogeneous composition of PBMC samples, it is
possible that the significant B cell pathway and oncosta-
tin M signalling observed in this study might be from B
cells, further illustrating the importance of examining a
homogeneous population of cells.
One obvious limitation of this study is that the sample
sizes are small, and therefore deemed likely to generate a
number of false positive genes. This effect is alleviated to
some extent by a prospective approach in sample collec-
tion and paired sample analyses. The independent applica-
tion of GSEA provided a strong supporting evidence for
the observed increased expression of mitochondrial
gene sets following good response to tocilizumab,
thereby validating this finding. We have also identified
genes/pathways previously known to be involved in
the pathogenesis of sJIA, suggesting that our findings
are not false positives.
It might be potentially important and interesting to
profile patients who do not clinically respond to IL-6R
blockade, assuming that their pathology is via a different
pathway. We have not addressed this question in this
initial study because the lack of the clinical response to
tocilizumab is a continuum that may be due to many
reasons. We feel that using a clinically well-defined full
response to drug therapy of ACR90 is better to observe
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significant differences and also allows us to collect suffi-
ciently similar patients to do statistical comparisons.
Conclusions
In conclusion, we have shown that mitochondrial genes
in neutrophils could play a role in the pathogenesis of
some sJIA patients, and highlight that it is important to
examine the neutrophils in future transcriptome ana-
lyses in sJIA, as has already been shown in polyarticular
JIA [21-23, 45, 46].
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